On Oct 31, major Wall Street analysts update their ratings for $Tenet Healthcare (THC.US)$, with price targets ranging from $183 to $217.
Goldman Sachs analyst Jamie Perse maintains with a buy rating, and adjusts the target price from $173 to $196.
BofA Securities analyst Joanna Gajuk maintains with a buy rating, and maintains the target price at $189.
UBS analyst A.J. Rice maintains with a buy rating, and adjusts the target price from $164 to $217.
RBC Capital analyst Ben Hendrix maintains with a buy rating, and adjusts the target price from $136 to $183.
Truist Financial analyst David S Macdonald maintains with a buy rating, and adjusts the target price from $180 to $190.
Furthermore, according to the comprehensive report, the opinions of $Tenet Healthcare (THC.US)$'s main analysts recently are as follows:
Tenet Healthcare displayed a robust performance across its various segments for the third quarter, particularly noting strong results from the hospital segment, with the USPI segment meeting expectations. The company is focusing on channeling investments towards the USPI segment as its primary capital allocation, while also continuing to seek growth opportunities within its hospitals, especially after refining its portfolio through a series of divestitures.
Tenet Healthcare demonstrated a notable recovery from previous weaknesses in the hospital segment, underscored by a robust third-quarter performance and an upward revision of future guidance. The company's preliminary outlook for 2025 indicates a persistence of robust volume trends into the upcoming year, alongside ongoing expansion of capacity.
Here are the latest investment ratings and price targets for $Tenet Healthcare (THC.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间10月31日，多家华尔街大行更新了$泰尼特 (THC.US)$的评级，目标价介于183美元至217美元。
高盛集团分析师Jamie Perse维持买入评级，并将目标价从173美元上调至196美元。
美银证券分析师Joanna Gajuk维持买入评级，维持目标价189美元。
瑞士银行分析师A.J. Rice维持买入评级，并将目标价从164美元上调至217美元。
加皇资本市场分析师Ben Hendrix维持买入评级，并将目标价从136美元上调至183美元。
储亿银行分析师David S Macdonald维持买入评级，并将目标价从180美元上调至190美元。
此外，综合报道，$泰尼特 (THC.US)$近期主要分析师观点如下：
以下为今日5位分析师对$泰尼特 (THC.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
